CLINICAL_TRIALS ClinicalTrials.gov record update

Hyperprogression Upon Cemiplimab Alone or With Chemotherapy in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial - HYPERBOLIC Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07274384
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:51.046368+00:00
Published At: 2025-12-10T00:00:00+00:00
Record Updated At: 2025-12-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["NSCLC (Non-small Cell Lung Cancer)", "Hyperprogression"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-10"
protocolSection.identificationModule.nctId: "NCT07274384"
protocolSection.identificationModule.officialTitle: "Hyperprogression Upon Cemiplimab Alone or With Chemotherapy in PD-L1 \u2265 50% NSCLC: a Biomarker Guided Phase 2 Trial - HYPERBOLIC Trial"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.